To ensure that the most important molecular markers are tested, quick and reliable testing with another method of hotspot regions of at least EGFR and KRAS (and preferably also BRAF) is needed for NSCLC adenocarcinomas to ensure optimal treatment possibilities with targeted therapy. This evidence concerns the gene EGFR and adenocarcinoma.